Smokers Who Completely Switch to our Smokeless Products
Smokers who completely switch to our Smokeless Products can achieve favourable changes in biomarkers of potential harm.
Like our clinical exposure studies, our clinical risk studies can be either Longitudinal or Cross-Sectional in design.
Longitudinal (Journey)
Cross-Sectional (Snapshot)
Our cross-sectional clinical studies have proven that adult consumers of Vuse and Velo have favourable differences in BoPH compared to adult smokers with some comparable to former smokers.*†[37],[38]
Standard deviations have been omitted from charts for ease of reading, Full figures are available in references: [37],[38]
Our longitudinal clinical study has proven that switching completely to glo can have favourable changes in BoPH compared to smokers with some comparable to former smokers.*†[36]
“Across our clinical studies, complete switching to our Smokeless Products resulted in statistically significant reductions in harmful chemical exposure and favourable shifts in biomarkers of potential harm versus continued smoking, approaching those seen with smoking cessation.*†”
Helen Cowie
Head of THR Sciences
Footnotes
* Based on the weight of evidence and assuming a complete switch from cigarette smoking. These products are not risk free and are addictive.
† Our products as sold in the U.S., including Vuse, Velo, Grizzly, Kodiak, and Camel Snus, are subject to FDA regulation and no reduced-risk claims will be made as to these products without agency clearance
^Not a BoPH but physiological measure
References
A full list of references for this page can be found in the section 11. References.
Exclusive access to the Omni™ Newsletter
Join the conversation shaping A Better Tomorrow™. Sign up to receive exclusive access to the Omni™ Newsletter and future Omni™ updates.
Signing up to the Omni™ Newsletter does not constitute consent to receive marketing communications.